Back to Archived News
Resolvyx Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials
Friday, September 18, 2009
Bedford, MA -- Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials. RX-10045 has been formulated as a topical eye drop that was recently evaluated in a Phase 2 clinical study showing positive results for the treatment of patients with chronic dry eye syndrome.
"Just last month, we reported positive results from a 232-patient Phase II trial in which RX-10045 improved both signs and symptoms of chronic dry eye," stated Greg Weinhoff, M.D., Executive Chairman of Resolvyx. "We are very pleased to have the first US patent covering this class of compounds that has the potential to be an important therapy for chronic dry eye syndrome and other ophthalmic diseases."
In addition to this patent, Resolvyx has an issued patent in Europe and a pending patent application in the US for RX-10001, an orally available Resolvin therapeutic currently in Phase 1 testing with potential to treat inflammatory bowel disease, asthma and other inflammatory diseases. The company has over 80 issued or pending patent applications in the U.S. and worldwide covering the resolvin platform of compounds.
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, Resolvins act to protect healthy tissue during an inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (e.g. Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (e.g. asthma) and chronic inflammatory diseases (e.g. atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease). Resolvins offer an entirely novel biological approach for the treatment of inflammatory diseases.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of over 80 patents and applications.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.
Back to Archived News